Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449735 · ClinicalTrials.gov registry record
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 500
- Enrollment target
NCT00449735 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 500 participants.
The verdict
NCT00449735 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed. Finally, outcome will be recorded - this is all-cause mortality at 28 days from the time of the first positive blood culture. Hypothesis: Ciprofloxacin resistant strains are associated with admission from nursing home and with prior quinolone use.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2007-03 |
| Est. Completion | 2017-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449735
The ClinicalTrials.gov registry entry for NCT00449735 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00449735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449735 about?
NCT00449735 is a clinical study titled "Quinolone Resistance in Bloodstream Isolates of Escherichia Coli". This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed. Finally, outcome will be recorded - this is all-cause mortality at 28 days ...
What is the current status of trial NCT00449735?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2007-03. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT00449735?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.